Bioventus Total Current Liabilities vs Total Stockholder Equity Analysis

BVS Stock

USD 5.04 0.08 1.56%

Bioventus financial indicator trend analysis is way more than just evaluating Bioventus prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bioventus is a good investment. Please check the relationship between Bioventus Total Current Liabilities and its Total Stockholder Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bioventus. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Bioventus Stock please use our How to Invest in Bioventus guide.

Total Current Liabilities vs Total Stockholder Equity

Total Current Liabilities vs Total Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bioventus Total Current Liabilities account and Total Stockholder Equity. At this time, the significance of the direction appears to have strong relationship.

The correlation between Bioventus' Total Current Liabilities and Total Stockholder Equity is 0.65. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Bioventus, assuming nothing else is changed. The correlation between historical values of Bioventus' Total Current Liabilities and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Bioventus are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Total Current Liabilities i.e., Bioventus' Total Current Liabilities and Total Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.65

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Total Current Liabilities

Total Current Liabilities is an item on Bioventus balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Bioventus are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most indicators from Bioventus' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bioventus current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bioventus. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Bioventus Stock please use our How to Invest in Bioventus guide.Enterprise Value is likely to gain to about 1.2 B in 2024, whereas Discontinued Operations is likely to drop (2.2 M) in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	1.1M	25.8M	40.7M	42.7M
Depreciation And Amortization	34.9M	66.8M	57.4M	41.5M

Interest Expense Depreciation And Amortization

Bioventus fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt
Common Stock Shares Outstanding		0.76	0.88	0.79	0.8	0.5	0.87	-0.15	0.83	-0.73	0.78	0.24	0.7	-0.29	0.24	0.83	-0.34	-0.67	0.77	0.87	0.75	0.9	0.79	0.97	0.82	0.64
Total Assets	0.76		0.91	0.73	0.94	0.86	0.86	0.17	0.89	-0.22	0.9	0.13	0.99	-0.48	0.13	0.87	0.11	-0.66	0.98	0.86	0.93	0.82	0.97	0.6	0.82	0.61
Short Long Term Debt Total	0.88	0.91		0.79	0.92	0.65	0.94	-0.01	0.97	-0.51	0.93	0.16	0.87	-0.42	0.16	0.93	-0.12	-0.65	0.93	0.98	0.89	0.87	0.93	0.78	0.89	0.68
Other Current Liab	0.79	0.73	0.79		0.84	0.33	0.71	-0.49	0.79	-0.6	0.91	0.02	0.71	-0.81	0.02	0.69	-0.59	-0.57	0.83	0.81	0.51	0.69	0.84	0.67	0.63	0.62
Total Current Liabilities	0.8	0.94	0.92	0.84		0.65	0.89	0.04	0.86	-0.42	0.94	0.26	0.9	-0.61	0.26	0.91	-0.15	-0.55	0.97	0.89	0.81	0.83	0.98	0.65	0.88	0.72
Total Stockholder Equity	0.5	0.86	0.65	0.33	0.65		0.62	0.44	0.67	0.19	0.58	-0.05	0.89	-0.13	-0.05	0.6	0.53	-0.67	0.74	0.56	0.89	0.63	0.72	0.37	0.54	0.39
Property Plant And Equipment Net	0.87	0.86	0.94	0.71	0.89	0.62		0.09	0.89	-0.47	0.82	0.26	0.8	-0.32	0.26	0.89	-0.09	-0.67	0.85	0.94	0.87	0.86	0.87	0.81	0.89	0.68
Current Deferred Revenue	-0.15	0.17	-0.01	-0.49	0.04	0.44	0.09		-0.14	0.44	-0.2	0.51	0.13	0.51	0.51	0.21	0.85	0.23	0.02	-0.13	0.37	0.08	0.03	-0.2	0.27	-0.15
Net Debt	0.83	0.89	0.97	0.79	0.86	0.67	0.89	-0.14		-0.42	0.93	-0.08	0.88	-0.46	-0.08	0.81	-0.13	-0.77	0.9	0.98	0.85	0.81	0.9	0.73	0.75	0.71
Retained Earnings	-0.73	-0.22	-0.51	-0.6	-0.42	0.19	-0.47	0.44	-0.42		-0.45	-0.38	-0.11	0.19	-0.38	-0.54	0.73	0.14	-0.32	-0.55	-0.17	-0.54	-0.35	-0.78	-0.56	-0.43
Accounts Payable	0.78	0.9	0.93	0.91	0.94	0.58	0.82	-0.2	0.93	-0.45		0.04	0.88	-0.71	0.04	0.84	-0.27	-0.6	0.96	0.92	0.75	0.76	0.96	0.63	0.77	0.69
Cash	0.24	0.13	0.16	0.02	0.26	-0.05	0.26	0.51	-0.08	-0.38	0.04		0.0	0.16	1.0	0.5	0.02	0.45	0.14	0.07	0.19	0.27	0.18	0.22	0.59	-0.09
Non Current Assets Total	0.7	0.99	0.87	0.71	0.9	0.89	0.8	0.13	0.88	-0.11	0.88	0.0		-0.51	0.0	0.79	0.15	-0.71	0.96	0.81	0.9	0.77	0.95	0.53	0.72	0.6
Non Currrent Assets Other	-0.29	-0.48	-0.42	-0.81	-0.61	-0.13	-0.32	0.51	-0.46	0.19	-0.71	0.16	-0.51		0.16	-0.33	0.52	0.26	-0.62	-0.45	-0.15	-0.23	-0.62	-0.12	-0.26	-0.39
Cash And Short Term Investments	0.24	0.13	0.16	0.02	0.26	-0.05	0.26	0.51	-0.08	-0.38	0.04	1.0	0.0	0.16		0.5	0.02	0.45	0.14	0.07	0.19	0.27	0.18	0.22	0.59	-0.09
Net Receivables	0.83	0.87	0.93	0.69	0.91	0.6	0.89	0.21	0.81	-0.54	0.84	0.5	0.79	-0.33	0.5		-0.04	-0.38	0.88	0.86	0.85	0.83	0.9	0.71	0.99	0.57
Good Will	-0.34	0.11	-0.12	-0.59	-0.15	0.53	-0.09	0.85	-0.13	0.73	-0.27	0.02	0.15	0.52	0.02	-0.04		0.06	-0.06	-0.23	0.31	-0.12	-0.09	-0.38	-0.04	-0.23
Common Stock Total Equity	-0.67	-0.66	-0.65	-0.57	-0.55	-0.67	-0.67	0.23	-0.77	0.14	-0.6	0.45	-0.71	0.26	0.45	-0.38	0.06		-0.6	-0.7	-0.66	-0.66	-0.59	-0.65	-0.33	-0.6
Non Current Liabilities Total	0.77	0.98	0.93	0.83	0.97	0.74	0.85	0.02	0.9	-0.32	0.96	0.14	0.96	-0.62	0.14	0.88	-0.06	-0.6		0.88	0.86	0.8	1.0	0.6	0.83	0.61
Inventory	0.87	0.86	0.98	0.81	0.89	0.56	0.94	-0.13	0.98	-0.55	0.92	0.07	0.81	-0.45	0.07	0.86	-0.23	-0.7	0.88		0.82	0.85	0.89	0.8	0.83	0.75
Other Current Assets	0.75	0.93	0.89	0.51	0.81	0.89	0.87	0.37	0.85	-0.17	0.75	0.19	0.9	-0.15	0.19	0.85	0.31	-0.66	0.86	0.82		0.83	0.85	0.64	0.83	0.5
Other Stockholder Equity	0.9	0.82	0.87	0.69	0.83	0.63	0.86	0.08	0.81	-0.54	0.76	0.27	0.77	-0.23	0.27	0.83	-0.12	-0.66	0.8	0.85	0.83		0.82	0.84	0.83	0.62
Total Liab	0.79	0.97	0.93	0.84	0.98	0.72	0.87	0.03	0.9	-0.35	0.96	0.18	0.95	-0.62	0.18	0.9	-0.09	-0.59	1.0	0.89	0.85	0.82		0.62	0.85	0.65
Property Plant And Equipment Gross	0.97	0.6	0.78	0.67	0.65	0.37	0.81	-0.2	0.73	-0.78	0.63	0.22	0.53	-0.12	0.22	0.71	-0.38	-0.65	0.6	0.8	0.64	0.84	0.62		0.72	0.6
Total Current Assets	0.82	0.82	0.89	0.63	0.88	0.54	0.89	0.27	0.75	-0.56	0.77	0.59	0.72	-0.26	0.59	0.99	-0.04	-0.33	0.83	0.83	0.83	0.83	0.85	0.72		0.53
Short Term Debt	0.64	0.61	0.68	0.62	0.72	0.39	0.68	-0.15	0.71	-0.43	0.69	-0.09	0.6	-0.39	-0.09	0.57	-0.23	-0.6	0.61	0.75	0.5	0.62	0.65	0.6	0.53

Click cells to compare fundamentals

Bioventus Account Relationship Matchups

Bioventus fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	56.8M	56.8M	59.5M	61.4M	62.6M	63.5M
Total Assets	472.4M	494.5M	1.2B	1.4B	810.9M	788.8M
Short Long Term Debt Total	198.0M	188.4M	357.7M	418.1M	409.5M	292.3M
Other Current Liab	15.6M	3.9M	3.6M	233.4M	115.8M	121.6M
Total Current Liabilities	89.0M	122.6M	180.9M	304.0M	175.5M	148.1M
Total Stockholder Equity	143.0M	142.2M	458.9M	316.6M	173.6M	240.5M
Property Plant And Equipment Net	19.8M	21.8M	40.2M	45.0M	50.0M	27.7M
Current Deferred Revenue	57.0M	99.2M	142.3M	4.7M	5.5M	5.2M
Net Debt	133.4M	101.5M	313.7M	386.3M	372.5M	247.3M
Retained Earnings	(141.7M)	(144.5M)	(6.6M)	(165.3M)	(321.5M)	(305.5M)
Accounts Payable	6.4M	4.4M	16.9M	37.5M	23.0M	15.2M
Cash	64.5M	86.8M	43.9M	31.8M	37.0M	45.0M
Non Current Assets Total	289.4M	282.7M	962.8M	1.1B	542.9M	576.9M
Non Currrent Assets Other	3.3M	19.4M	50M	(154.0M)	3.1M	3.3M
Cash And Short Term Investments	64.5M	86.8M	43.9M	31.8M	37.0M	45.0M
Net Receivables	85.1M	88.3M	125.0M	136.6M	123.0M	100.7M
Liabilities And Stockholders Equity	472.4M	494.5M	1.2B	1.4B	810.9M	788.8M
Non Current Liabilities Total	237.8M	227.7M	511.2M	728.3M	414.3M	379.4M
Inventory	27.3M	29.1M	61.7M	85.4M	91.3M	52.8M
Other Current Assets	6.1M	7.6M	27.2M	18.7M	16.7M	12.7M
Other Stockholder Equity	(168M)	287.1M	465.3M	481.9M	494.3M	519.0M
Total Liab	326.8M	350.3M	692.1M	1.0B	589.8M	527.5M
Property Plant And Equipment Gross	19.8M	21.8M	40.2M	45.0M	90.5M	95.0M
Total Current Assets	183.0M	211.8M	263.1M	272.6M	268.0M	212.0M
Accumulated Other Comprehensive Income	(465K)	1.6M	179K	(110K)	794K	833.7K
Short Term Debt	10M	15M	18.0M	33.1M	31.9M	21.8M
Intangible Assets	216.5M	191.7M	695.2M	1.0B	482.4M	475.1M
Common Stock	285.1M	285.2M	75K	78K	79K	75.1K
Long Term Debt	188.0M	173.4M	339.6M	385.0M	367.0M	301.1M
Net Invested Capital	340.9M	330.6M	816.6M	734.6M	568.4M	574.1M
Long Term Investments	3.3M	19.4M	29.3M	2.6M	3.0M	2.9M
Short Long Term Debt	10M	15M	18.0M	33.1M	27.8M	20.0M
Capital Stock	285.1M	285.2M	75K	78K	79K	75.1K
Non Current Liabilities Other	20.7M	21.7M	38.1M	110.0M	46.1M	44.4M

Pair Trading with Bioventus

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bioventus position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bioventus will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bioventus Stock

0.72

FEMY

Femasys Financial Report 9th of May 2024

Pair Corr

Moving against Bioventus Stock

0.52

DYNT

Dynatronics Financial Report 9th of May 2024

Pair Corr

The ability to find closely correlated positions to Bioventus could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bioventus when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bioventus - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bioventus to buy it.

The correlation of Bioventus is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bioventus moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bioventus moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Bioventus can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Bioventus is a strong investment it is important to analyze Bioventus' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bioventus' future performance. For an informed investment choice regarding Bioventus Stock, refer to the following important reports:

How To Invest In Bioventus

Details

Is Bioventus Stock a good investment?

Details

What is Bioventus' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bioventus. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Bioventus Stock please use our How to Invest in Bioventus guide.

You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Bioventus Stock analysis

When running Bioventus' price analysis, check to measure Bioventus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioventus is operating at the current time. Most of Bioventus' value examination focuses on studying past and present price action to predict the probability of Bioventus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioventus' price. Additionally, you may evaluate how the addition of Bioventus to your portfolios can decrease your overall portfolio volatility.

	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Bonds Directory Find actively traded corporate debentures issued by US companies
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm

Is Bioventus' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bioventus. If investors know Bioventus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bioventus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.54)

Revenue Per Share

8.178

Quarterly Revenue Growth

0.076

Return On Assets

0.0012

Return On Equity

(0.38)

The market value of Bioventus is measured differently than its book value, which is the value of Bioventus that is recorded on the company's balance sheet. Investors also form their own opinion of Bioventus' value that differs from its market value or its book value, called intrinsic value, which is Bioventus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bioventus' market value can be influenced by many factors that don't directly affect Bioventus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bioventus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bioventus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bioventus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bioventus Total Current Liabilities vs Total Stockholder Equity Analysis

Total Current Liabilities vs Total Stockholder Equity

Total Current Liabilities vs Total Stockholder Equity Correlation Analysis

Correlation Coefficient

Total Current Liabilities

Total Stockholder Equity

Bioventus fundamental ratios Correlations

Bioventus Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bioventus fundamental ratios Accounts

Pair Trading with Bioventus

Moving together with Bioventus Stock

Moving against Bioventus Stock

Complementary Tools for Bioventus Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Liab	+ 1.0	Non Current Liabilities Total
Non Current Assets Total	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Net Receivables
Non Current Liabilities Total	+ 0.98	Total Assets
Inventory	+ 0.98	Short Long Term Debt Total

Non Currrent Assets Other	- 0.81	Other Current Liab
Property Plant And Equipment Gross	- 0.78	Retained Earnings
Common Stock Total Equity	- 0.77	Net Debt
Retained Earnings	- 0.73	Common Stock Shares Outstanding
Common Stock Total Equity	- 0.71	Non Current Assets Total
Non Currrent Assets Other	- 0.71	Accounts Payable